Oral LY217896 for prevention of experimental influenza A virus infection and illness in humans.
about
The Influenza Virus Polymerase Complex: An Update on Its Structure, Functions, and Significance for Antiviral Drug DesignReducing the impact of the next influenza pandemic using household-based public health interventionsWITHDRAWN: Antivirals for the common cold.Approaches and strategies for the treatment of influenza virus infections.Multi-scale modeling for the transmission of influenza and the evaluation of interventions toward it.Accelerating Influenza Research: Vaccines, Antivirals, Immunomodulators and Monoclonal Antibodies. The Manufacture of a New Wild-Type H3N2 Virus for the Human Viral Challenge ModelNew trends in nucleoside biotechnologyDevelopment of antivirals against influenza.An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with InfectionAnti-influenza virus agents: synthesis and mode of action.Human challenge studies: a review of adequacy of reporting methods and results.Synthesis and Anti-Hepatitis B Virus Evaluation of 7-Methoxy-3-heterocyclic quinolin-6-ols.Using experimental human influenza infections to validate a viral dynamic model and the implications for prediction.Recognition of Artificial Nucleobases by E. coli Purine Nucleoside Phosphorylase versus its Ser90Ala Mutant in the Synthesis of Base-Modified Nucleosides.The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics.
P2860
Q28071809-6C2652EC-2327-4F92-BA0E-09676E348FE2Q28768241-F86C60C0-1ADE-4DE6-8E80-CF6B762EB075Q33291075-17F2DB3B-B3A7-4D63-A8E7-1C5C2541551AQ33730165-11345FAE-7A12-4AE9-BB40-741829E90A13Q35165807-8004A89B-1F23-4BBA-A6BC-B6F306A38DFCQ35892839-9BACFF65-19AD-4404-B3D6-BDEA721D1DC2Q35944327-7BDC2B75-8757-49CE-A24A-C91A48FD5780Q36181153-B5000E79-ED0B-4447-9C6A-D99444E244CFQ36231510-62369D0A-2BC9-4D65-9237-EC9BC68D3D07Q36679637-11E53DB9-BC3B-4B39-A3A4-79F7AB0977FDQ37996090-5925F0C5-C03C-4545-8354-752424A63BCBQ38830360-4226C7EA-91CD-488D-9221-FC16D76063B8Q45834866-E7F5B930-18E5-44DE-9815-97C3E47B1559Q54263301-7A4641D3-4A76-467C-8108-B90A73E94CDAQ55447639-CDDFB452-09F7-4074-A87A-2B7C934EB0F5
P2860
Oral LY217896 for prevention of experimental influenza A virus infection and illness in humans.
description
1994 nî lūn-bûn
@nan
1994 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Oral LY217896 for prevention o ...... fection and illness in humans.
@ast
Oral LY217896 for prevention o ...... fection and illness in humans.
@en
type
label
Oral LY217896 for prevention o ...... fection and illness in humans.
@ast
Oral LY217896 for prevention o ...... fection and illness in humans.
@en
prefLabel
Oral LY217896 for prevention o ...... fection and illness in humans.
@ast
Oral LY217896 for prevention o ...... fection and illness in humans.
@en
P2093
P2860
P356
P1476
Oral LY217896 for prevention o ...... fection and illness in humans.
@en
P2093
Allerheiligen S
Treanor JJ
P2860
P304
P356
10.1128/AAC.38.5.1178
P407
P577
1994-05-01T00:00:00Z